Famotidine Continues to be Successful in Studies

Famotidine Continues to be Successful in Studies

Gastroesophageal reflux barium X-rayFamotidine, CAS number 76824-35-6, is an effective, tolerable and well- studied treatment for patients with both peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Schwarz Pharma holds the patent for this cogent medication, as the brand name Fluxid, with an expiration due on April 9, 2018.  As an H2 receptor, or histamine blocker receptor, famotidine works by binding to these receptors located on the membrane of the parietal cell. The ability of famotidine to bind and block histamine effects also leads to a reduced basal and gastric acid secretion. Famotidine is currently approved for the maintenance and short-term treatment of active duodenal ulcers,  the short-term treatment of active benign gastric ulcers, and the short –term treatment of gastroesophageal reflux disease, or GERD.  Patients who have of esophagitis as a result of GERD, such as erosive or ulcerative disease and patients with hypersecretory conditions like Zollinger-Ellison Syndrome may also be prescribed famotidine. Dizziness, diarrhea and headache are common side effects, but they are generally mild. Care should be taken when treating patients who are taking certain other medications, as these drugs can interfere with the effectiveness of famotidine. Examples of these medications are atazanavir, enoxacin, itraconazole and ketoconazole. For medications like itraconazole and ketoconazole the efficacy of these drugs are decreased when taken along with famotidine.

FamotidineClinical studies are still progressing for famotidine, with results revealing this medication to be reliably successful. One study, published September 14, 2012, offered uplifting news in terms of ulcer prevention and the use of famotidine. The study combined treatment with famotidine and ibuprofen in a new combination pill coined Duexis. When compared with patients dosed only with ibuprofen, the patients who took the combination Duexis pill had documented half as many ulcers. Patients were observed via endoscopies after 24 weeks of treatment with either ibuprofen or the famotidine and ibuprofen combination pill.  The study was funded by Horizon Pharma, the makers of the Duexis combination pill.

With roughly one-third of the U.S. population suffering from gastroesophageal reflux disease and related conditions, the advent of novel and effectual medications to treat these patients is clearly in demand.

LGM Pharma provides famotidine for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:
This website uses cookies. By using our site, you agree to our terms of service